Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Rev Allergy Immunol ; 44(2): 173-82, 2013 Apr.
Article in English | MEDLINE | ID: mdl-22426927

ABSTRACT

Psoriasis and psoriatic arthritis are chronic inflammatory diseases of unknown etiology, affecting 2-3% of the world population. Initially, psoriasis was thought to be a hyper-proliferation disorder of keratinocytes only, but as time passed, the role of immune system became more evident and now both diseases are considered autoimmune disorders. In last few years, the discovery of interleukin (IL)-23/Th17 axis in pathophysiology of psoriatic diseases shifts the cytokine paradigm from Th1 to Th17 cytokines, focused mainly on IL-17 and IL-22. Therapeutic experiences strongly support the use of cytokine antagonists as an important modality in the treatment of psoriatic arthritis and plaque psoriasis. Studies examining these therapeutic agents which target different steps of the psoriatic inflammatory cascade have also shown significant efficacy. The relatively new IL-23/Th17 axis in psoriatic diseases got more importance with the success of ustekinumab, a new monoclonal antibody against IL-12 and IL-23. In IL-17 and IL-22 knock-out and transgenic mouse models, it has been found that recombinant IL-23 fails to produce epidermal hyperplasia which resembles psoriasis. Also, some success in animal models of psoriasis was found with anti IL-17A and anti IL-22. More studies are needed to validate the efficacy and safety of these cytokine antagonists in psoriatic diseases. Using a historical perspective and a chess game as an analogy, the main objective of this review is to summarize the central role of some of these cytokines in psoriasis pathophysiology and to develop a strategic approach to new therapeutic weapons within the armamentarium of psoriasis treatment.


Subject(s)
Cytokines/immunology , Immunotherapy/methods , Psoriasis/immunology , Psoriasis/therapy , Th17 Cells/immunology , Animals , Antibodies, Monoclonal, Humanized/therapeutic use , Arthritis, Psoriatic/immunology , Arthritis, Psoriatic/therapy , Autoimmunity , Cytokines/antagonists & inhibitors , Disease Models, Animal , Humans , Immunotherapy/trends , Mice , Th1 Cells/immunology , Ustekinumab
2.
Skin Therapy Lett ; 17(10): 1-4, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23223767

ABSTRACT

Rosacea is a common chronic skin disorder that has significant impact on the self-esteem and quality of life of affected individuals. Currently understood as an inflammatory condition that occurs in the context of an altered innate immune response, the available topical and systemic therapies function as immunomodulators to restore cutaneous homeostasis. The goals of therapy include reduction of papules, pustules, erythema and physical discomfort with improvement in quality of life. Standard topical treatments include metronidazole and azelaic acid, although many other agents and regimens have been presented. Subantimicrobial/antiinflammatory dose oral doxycycline was US FDA approved in 2006 for the management of rosacea, but Health Canada clearance was only recently granted for this indication. Furthermore, renewed research interest has led to the development of other emerging therapies including topical ivermectin, brimonidine and oxymetazoline that hold promise for patients suffering from this condition.


Subject(s)
Adrenergic Agents/administration & dosage , Anti-Infective Agents/administration & dosage , Antiparasitic Agents/administration & dosage , Dermatologic Agents/administration & dosage , Rosacea/drug therapy , Administration, Cutaneous , Brimonidine Tartrate , Dicarboxylic Acids/administration & dosage , Doxycycline/administration & dosage , Female , Humans , Ivermectin/administration & dosage , Male , Metronidazole/administration & dosage , Oxymetazoline/administration & dosage , Quality of Life , Quinoxalines/administration & dosage , Randomized Controlled Trials as Topic , Rosacea/physiopathology , Sulfacetamide/administration & dosage , Treatment Outcome
3.
J Cutan Med Surg ; 16(3): 174-9, 2012.
Article in English | MEDLINE | ID: mdl-22713440

ABSTRACT

BACKGROUND: Fewer dermatologists than other clinical specialists are entering and being retained as physicians in the Canadian medical workforce. Studies suggest that dermatologist numbers may influence skin disease outcomes. No study has questioned whether the number of clinical dermatologists can influence academic productivity. OBJECTIVE: To quantify the correlation of the number of dermatologists with biomedical scientific production in this field from 1996 to 2008 in Canada. METHODS: Canadian dermatology biomedical scientific production from SCImago Journal & Country Rank (SJR) were merged with Canadian Medical Association (CMA) dermatologist demographic data. Linear regression analyses were used to model the relationships. RESULTS: The low growth of dermatologist numbers by 8.16% in Canada from 1996 to 2008 correlates with a small increase in articles by 7.59% published in this subject area during this period. This has reduced the scientific importance of Canadian dermatology in the world. CONCLUSION: The number of dermatologists was a significant predictor of biomedical research production in the field of dermatology. This suggests that specialist availability may be one factor influencing dermatology research and publications.


Subject(s)
Biomedical Research , Dermatology , Publishing/statistics & numerical data , Canada , Female , Humans , Linear Models , Male , Workforce
4.
Med Clin North Am ; 96(3): 565-82, x-xi, 2012 May.
Article in English | MEDLINE | ID: mdl-22703856

ABSTRACT

Treatment modalities and therapeutic response experience support the use of immunotherapy in the treatment of many diseases in all fields of medicine. The aim of this article is to conduct and present a review of literature on the use of immunotherapy in the treatment of skin diseases analyzing scientific literature available up to January 2012. Studies that presented evidence-based data were selected. The article discusses how blocking or reverting the effect of a specific immunologic disequilibrium can treat dermatoses and intends to transfer a large amount of immunotherapy knowledge into a historical perspective for physicians naive to immunotherapy practices.


Subject(s)
Skin Diseases/therapy , Adalimumab , Alefacept , Alemtuzumab , Antibodies, Anti-Idiotypic/therapeutic use , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Basiliximab , Dermatologic Agents/therapeutic use , Etanercept , Humans , Immunoglobulin G/therapeutic use , Immunoglobulins, Intravenous/therapeutic use , Ipilimumab , Omalizumab , Receptors, Tumor Necrosis Factor/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Rituximab , Skin Diseases/immunology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Ustekinumab
5.
Skin Therapy Lett ; 17(2): 1-3, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22358305

ABSTRACT

The incidence of nonmelanoma skin cancer continues to increase. While surgical excision remains the mainstay of treatment, growing demand from patients for effective, tissue-sparing approaches with good cosmetic results has led to the development of novel therapeutic agents. Several studies have reported on the safety and efficacy of topical ingenol mebutate gel, a derivative of the plant Euphorbia peplus, in the treatment of actinic keratosis and superficial basal cell carcinoma. An understanding of the history, mechanism of action, and recent trial evidence for this emerging therapy can assist physicians in counseling patients on available treatment options and in selecting appropriate therapy.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Diterpenes/therapeutic use , Skin Neoplasms/drug therapy , Administration, Cutaneous , Antineoplastic Agents, Phytogenic/adverse effects , Antineoplastic Agents, Phytogenic/pharmacology , Carcinoma, Basal Cell/drug therapy , Carcinoma, Basal Cell/pathology , Diterpenes/adverse effects , Diterpenes/pharmacology , Euphorbia/chemistry , Humans , Keratosis, Actinic/drug therapy , Keratosis, Actinic/pathology , Skin Neoplasms/pathology , Skin Neoplasms/surgery
6.
Skin Therapy Lett ; 16(6): 5-7, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21833462

ABSTRACT

The common bedbug (Cimex lectularius) is increasingly prevalent and a source of concern and questions for patients. In addition to a range of cutaneous presentations and potential for serious sequelae, bedbug bites cause significant psychological distress and create an economic burden associated with infestation control. Recognition of characteristic entomology, clinical presentation, diagnostic features and differential diagnosis can support expedient identification of patients exposed to infestations and support their appropriate management.


Subject(s)
Bedbugs , Ectoparasitic Infestations/prevention & control , Insect Bites and Stings/diagnosis , Animals , Bedding and Linens , Diagnosis, Differential , Ectoparasitic Infestations/diagnosis , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...